期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 62, 期 1, 页码 39-43出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2012.06.009
关键词
Cytokines; Inflammatory cells; Metformin; Pleiotropic effects; Statins
资金
- State Committee for Scientific Research [2 P05F 036 29]
Objective. This study was designed to investigate whether metformin affects monocyte secretory function in patients with impaired fasting glucose receiving chronic statin therapy. Materials/Methods. The study included 48 patients with impaired fasting glucose treated for at least three months with simvastatin (40 mg daily). These patients were randomized to either metformin (3 g daily) or placebo, which was administered together with simvastatin for 90 days. Plasma lipids, glucose homeostasis markers, monocyte cytokine release and plasma C-reactive protein levels were determined before randomization and at the end of the treatment. Results. Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1 beta,, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Conclusions. The obtained results suggest that metformin may inhibit monocyte secretory function and reduce systemic inflammation in statin-treated patients with prediabetes. Impaired fasting glucose patients with high cardiovascular risk may receive the greatest benefits from concomitant treatment with a statin and metformin. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据